Document:

Exhibit

Exhibit 10(ss)

Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.  Information that has been omitted has been noted in this document with a placeholder identified by the term “{redacted}”.  

	
														
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE
	PAGE OF PAGES

	 
	 
	1
	4

	2. AMENDMENT/MODIFICATION NO.
P00018
	3. EFFECTIVE DATE
See Block 16C
	4. REQUISITION/PURCHASE REQ. NO.

	5. PROJECT NO. (If applicable)

	6. ISSUED BY   CODE
	ASPR-BARDA
	7. ADMINISTERED BY (If other than Item 6)   CODE
	ASPR-BARDA02

	ASPR-BARDA 
200 Independence Ave., S.W. 
Room 640-G 
Washington DC 20201
	ASPR-BARDA 
330 Independence Ave, SW, Rm G640 
Washington DC 20201

	8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
	(x)
	9A. AMENDMENT OF SOLICITATION NO.

	SIGA TECHNOLOGIES, INC. 1385150
	 
	 

	SIGA TECHNOLOGIES, INC.                 35 E 6
	 
	9B. DATED (SEE ITEM 11)

	35 E 62ND ST
	 
	 

	NEW YORK NY 100658014
	x
	10A. MODIFICATION OF CONTRACT/ORDER NO. 
HHSO100201100001C

	 
	 
	 

	CODE  
1385150
	FACILITY CODE
	 
	10B. DATED (SEE ITEM 13)
05/13/2011

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	☐   The above numbered solicitation is amended as set forth in Item 14.  The hour and date specified for receipt of Offers   ☐is extended, ☐ is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning _____________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required) 
See Schedule

	13. THIS ITEM ONLY APPLIES TO MODIFICATIONS OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK ONE
	A.   THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 

	 
	B.   THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

	X
	C.   THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 43.103(a) - Bilateral Modification by Mutual Agreement of the Parties

	 
	D.   OTHER (Specify type of modification and authority)

	E. IMPORTANT:
	Contractor   ☐ is not   ☒ is required to sign this document and return   1   copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

	Tax ID Number: 13-3864870
DUNS Number: 932651516
Modification 18 accomplishes the following administrative actions:
1.)   Revises Subsection B.4.1 outlining reconciliation of contract budget and status of CLINs
2.)   Revises Subsection B.6.1.5.2. increasing Contracting Officer’s Authorization threshold from $100,000 to $250,000
3.)   Revises Subsection G.1 changing the Contracting Officer to George J. Keane, Jr.
Continued ...

	Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print)
Dennis E. Hruby, Chief Scientific Officer
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
GEORGE J. KEANE

	15B. CONTRACTOR/OFFEROR
/s/ Dennis E. Hruby   
(Signature of person authorized to sign)
	15C. DATE SIGNED
19 November 2019
	16B. UNITED STATES OF AMERICA
/s/ George J. Keane   
(Signature of Contracting Officer)
	16C. DATE SIGNED
20 November 2019

		
	Previous edition unusable
	STANDARD FORM 30 (REV 11/2016) 
Prescribed by GSA FAR (48 CFR) 53.243

	
									
	CONTINUATION SHEET
	REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSO100201100001C/P00018
	PAGE OF

	2
	4

	NAME OF OFFEROR OR CONTRACTOR
SIGA TECHNOLOGIES, INC. 1385150

	ITEM NO.
	SUPPLIES/SERVICES
	QUANTITY
	UNIT
	UNIT PRICE
	AMOUNT

	(A)
	(B)
	(C)
	(D)
	(E)
	(F)

	 
	4.)   Revises Subsection G.2 changing the Contracting Officer’s Representative to David Simon, Ph.D.
See supplemental pages for additional information. All other terms and conditions of contract HHSO100201100001C remain unchanged.
Period of Performance:  06/28/2016 to 09/24/2020
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 

		
	NSN 7540-01-152-8067
	OPTIONAL FORM 336 (4-86) 
Sponsored by GSA 
FAR (48 CFR) 53.110

Beginning with the effective date of this modification, the U.S. Government and Contractor mutually agree as follows:
		
	1)
	Revise SUBSECTION B.4.1 – Formerly titled “Reserved” to be retitled “Financial Reconciliation between Contractor and U.S. Government” and the following language inserted into that subsection:

At the close of FY2018, expiring funds were removed from the contract via Contract Modification 0017 (MOD 17). The sum of funds expiring from the contract differed between SIGA’s records and what was presented in MOD 17 by $9,845,100.69 (see below). The major source of the discrepancy was the expiration of approximately $9,364,500 from CLIN 0007, Contract Modification 0006 (effective 19 December 2012). Per BARDA’s internal protocols, the method by which these particular funds expired prevented them from being captured in MOD 17.
Expected de-Obligation per SIGA    -$13,683,010.54 
Actual de-obligation per MOD 17    -$3,837,909.85      
Difference    $9,845,100.69
Other minor, discrepancies were identified; however, Contractor (“SIGA”) and U.S. Government (“BARDA”) are in agreement that the work carried out under Contract CLINs 0001, 0002, 0003, 0004, 0005, 0006, 0011, 0022, 0007, 0007.2, 0007.6, 0008, 0009, 0009.6, and 0017 are complete and all invoices associated with these CLINs have been paid by BARDA. These CLINs show a $0 (zero) balance. Further, SIGA and BARDA are in agreement that as of the start of FY 2019-2020, the funds remaining on the contract (i.e. funds for which SIGA has not yet invoiced the government) total $3,776,740 (see table).
	
					
	CLIN
	Scope
	Budget ($)
	Status
	Remaining Budget ($)

	1, 2, 3, 4, 5, 6, 11, 22
	{redacted}
	462,236,945
	Complete
	0

	7.0
	{redacted}
	10,566,308
	Complete
	0

	7.2
	{redacted}
	1,925,485
	Complete
	0

	7.6
	{redacted}
	17,983,134
	Complete
	0

	7.12
	{redacted}
	4,813,377
	Ongoing
	2,086,201

	7.14
	{redacted}
	2,006,218
	Ongoing
	854,342

	8.0
	{redacted}
	4,143,641
	Complete
	0

	8.11
	{redacted}
	2,082,082
	Ongoing
	823,927

	9.0
	{redacted}
	659,877
	Complete
	0

	9.6
	{redacted}
	338,391
	Complete
	0

	17.0
	{redacted}
	1,690,598
	Complete
	0

	18.0
	{redacted}
	12,694
	Ongoing
	6,190

	21.0
	{redacted}
	12,694
	Ongoing
	6,080

	Remaining funds as of 01 October 2019 (FY19-20)
	3,776,740

		
	2)
	Revise SUBSECTION B.6.1.5.2 – Change language to the following increasing Contracting Officer’s Authorization (COA) threshold from $100,000 to $250,000:

Award of any FFP subcontract or FFP consulting agreement in excess of $250,000 or any cost reimbursement, labor hour subcontract or consulting agreement funded under a Cost Plus Fixed Fee CLIN shall not proceed without the prior written consent of the Contracting Officer via a Contracting Officer Authorization (COA) Letter upon review of the supporting documentation required by FAR Clause 52.244-2, Subcontracts. After receiving written consent of the subcontract by the Contracting Officer, a copy of the signed, executed subcontract and consulting agreement shall be provided to the Contracting Officer.
		
	3)
	SUBSECTION G.1 CONTRACTING OFFICER 

The Contracting Officer is hereby changed to:
George J. Keane, Jr. 
Team Lead / Contracting Officer – CBRN, Flu, PBS 
Station Support & Administrative Branch 
Division of Contracts Management & Acquisition 
Biomedical Advanced Research & Development Authority (BARDA) 
Office of Secretary for Preparedness & Response (ASPR) 
Department of Health and Human Services
Mailing Address: 
{redacted}
		
	4)
	ARTICLE G.2 CONTRACTING OFFICER’S REPRESENTATIVE (COR) 

The COR is hereby changed to:
David Simon, Ph.D. 
Health Scientist / Antiviral Antitoxin Branch 
Division of CBRN Countermeasures 
Biomedical Advanced Research & Development Authority (BARDA) 
Office of Secretary for Preparedness & Response (ASPR) 
Department of Health and Human Services
Mailing Address: 
{redacted}
END OF MODIFICATION 18 of HHSO100201100001Csyrs-ex41_719.htm

 

Exhibit 4.1

DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT 

The following description of the common stock, par value $0.001 per share (the “Common Stock”) of Syros Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), summarizes certain information regarding the Common Stock in our Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), our Amended and Restated By-laws (the “By-laws”) and applicable provisions of Delaware General Corporation Law (the “DGCL”), and is qualified by reference to the Certificate of Incorporation and the By-laws, which are incorporated by reference as Exhibit 3.1 and Exhibit 3.2, respectively, to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part.

 

Authorized Capital Stock 

Our authorized capital stock consists of 200,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, par value $0.001 per share (the “Preferred Stock”).

 

Common Stock

 

Holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders is determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Other matters are decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter, except as otherwise disclosed below. Holders of Common Stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding Preferred Stock.

 

In the event of our liquidation or dissolution, the holders of Common Stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding Preferred Stock. Holders of Common Stock have no preemptive, subscription, redemption or conversion rights, and there are no sinking fund provisions applicable to our Common Stock. The rights, preferences and privileges of holders of Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of Preferred Stock that we may designate and issue in the future.

 

Registration Rights

 

Amended and Restated Investors’ Rights Agreement. The amended and restated investors’ rights agreement, dated as of October 9, 2014, as amended, which we refer to as our investors’ rights agreement, by and among our company and certain of our stockholders, provides specified holders of our previously outstanding Preferred Stock, including some of our directors and 5% stockholders and their respective affiliates and entities affiliated with our officers and directors, the right to require us to register the shares of Common Stock that were issued upon conversion of the Preferred Stock under the Securities Act under specified circumstances as described below. After registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act.

 

 

ActiveUS 178254164v.3

 

Demand Registration Rights. Subject to specified limitations set forth in our investors’ rights agreement, at any time the holders of 25% of then outstanding registrable securities, as defined in the investor’s rights agreement, acting together, may demand in writing that we register their registrable securities under the Securities Act so long as the total amount of registrable shares requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, as defined in the investors’ rights agreement, that would exceed $5.0 million. We are not obligated to effect a registration statement pursuant to this demand provision on more than two occasions, subject to specified exceptions.

 

In addition, at any time that we are eligible to file a registration statement on Form S-3 under the Securities Act, subject to specified limitations, the holders of at least 25% of the registrable securities then outstanding may demand in writing that we register on Form S-3 registrable shares held by them so long as the total amount of registrable shares requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, as defined in the investors’ rights agreement, of at least $2.0 million. We are not obligated to effect a registration statement pursuant to this demand provision on more than two occasions in any twelve-month period, subject to specified exceptions.

 

Incidental Registration Rights. If, at any time, we propose to file a registration statement to register any of our securities under the Securities Act, either for our own account or for the account of any of our stockholders that are not holders of registrable shares, solely for cash and on a form that would also permit the registration of registrable shares, the holders of our registrable shares are entitled to notice of registration and, subject to specified exceptions, we will be required to register the registrable shares then held by them that they request that we register.

 

Expenses. Pursuant to the investor’s rights agreement, we are required to pay all registration expenses, including registration fees, printing expenses, fees and disbursements of our counsel and accountants and reasonable fees and disbursements of one counsel representing the selling stockholders, other than any underwriting discounts and commissions, related to any demand or incidental registration. The investor’s rights agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them.

 

Anti-Takeover Effects of Delaware Law and Our Charter and By-laws

 

Delaware law and our Certificate of Incorporation and our By-laws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.

 

 

ActiveUS 178254164v.2

 

Staggered Board; Removal of Directors. Our Certificate of Incorporation and our By-laws divide our board of directors into three classes with staggered three-year terms. In addition, a director may only be removed for cause and only by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may only be filled by vote of a majority of our directors then in office. The classification of our board of directors and the limitations on the removal of directors and filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.

 

Stockholder Action by Written Consent; Special Meetings. Our Certificate of Incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Our Certificate of Incorporation and our By-laws also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by our chairman of the board, our chief executive officer or our board of directors.

 

Advance Notice Requirements for Stockholder Proposals. Our By-laws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder’s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities.

 

Delaware Business Combination Statute. We are subject to Section 203 of the DGCL. Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for three years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A “business combination” includes, among other things, a merger or consolidation involving us and the “interested stockholder” and a sale involving us and the “interested stockholder” of 10% or more of our assets. In general, an “interested stockholder” is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.

 

 

ActiveUS 178254164v.2

 

Amendment of Certificate of Incorporation and By-laws. The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s Certificate of Incorporation or By-laws, unless a corporation’s Certificate of Incorporation or By-laws, as the case may be, requires a greater percentage. Our By-laws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our Certificate of Incorporation described above under “—Staggered Board; Removal of Directors” and “—Stockholder Action by Written Consent; Special Meetings.”

  

Authorized but Unissued Shares

 

The authorized but unissued shares of Common Stock and Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of The Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

 

ActiveUS 178254164v.2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]